The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A - IV | Alive

Total Raised


Last Raised

$10M | 2 yrs ago

About Orbus Therapeutics

Orbus Therapeutics is a private, clinical-stage biopharmaceutical company is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The Company's product candidate in clinical development is eflornithine. Eflornithine is a cytostatic agent, which the Company is developing to treat patients with recurrent anaplastic astrocytoma (rAA), a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.

Orbus Therapeutics Headquarter Location

2479 East Bayshore Road Suite 105

Palo Alto, California, 94303,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Orbus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Orbus Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Orbus Therapeutics Patents

Orbus Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Brain tumor
  • Oncology
  • Cerebrum
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Brain tumor, Prodrugs, Oncology, MicroRNA


Application Date


Grant Date



Related Topics

Transcription factors, Brain tumor, Prodrugs, Oncology, MicroRNA



Latest Orbus Therapeutics News

Ornithine Decarboxylase (ODC) Inhibitor Pipeline Insight Report 2022 Featuring Orbus Therapeutics, Aminex Therapeutics, Genzyme, Nippon Kayaku, & Cancer Prevention Pharmaceuticals -

Jun 29, 2022

"Ornithine Decarboxylase (ODC) Inhibitor - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Ornithine Decarboxylase (ODC) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Ornithine Decarboxylase (ODC) Inhibitor Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for Ornithine Decarboxylase (ODC) Inhibitor The report assesses the active Ornithine Decarboxylase (ODC) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route. Reasons to Buy Establish a comprehensive understanding of the current pipeline scenario across Ornithine Decarboxylase (ODC) Inhibitor to formulate effective R&D strategies Assess challenges and opportunities that influence Ornithine Decarboxylase (ODC) Inhibitor research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought-after therapy areas and indications for Ornithine Decarboxylase (ODC) Inhibitor Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Ornithine Decarboxylase (ODC) Inhibitor to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress The extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs Key Topics Covered:

Orbus Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Orbus Therapeutics Rank

  • Where is Orbus Therapeutics's headquarters?

    Orbus Therapeutics's headquarters is located at 2479 East Bayshore Road, Palo Alto.

  • What is Orbus Therapeutics's latest funding round?

    Orbus Therapeutics's latest funding round is Series A - IV.

  • How much did Orbus Therapeutics raise?

    Orbus Therapeutics raised a total of $71M.

  • Who are the investors of Orbus Therapeutics?

    Investors of Orbus Therapeutics include Longitude Capital, H.I.G. BioHealth Partners, Abingworth, Adams Street Partners, Pappas Ventures and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.